Mode
Text Size
Log in / Sign up

Infection status associated with hypoxemia and death rates varying by virus type in a large US cohortTriple Virus Infections Rarer Than Feared — Here’s the Real Risk

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that hypoxemia and death rates vary by virus type in this observational cohort of 835,987 patients.

This cohort study analyzed data from 835,987 triple-tested patients within the US Veterans Health Administration. The population included individuals tested for SARS-CoV-2, influenza, and respiratory syncytial virus (RSV). The primary outcomes assessed were hypoxemia, defined as SpO2 requiring 2 L/min, or death.

The study compared infection groups: SARS-CoV-2 alone, influenza alone, RSV alone, multiple viruses, and all-negative tests. Hypoxemia was observed in 8.0% of patients with SARS-CoV-2 alone (170,592 positive tests), 7.7% with influenza alone (30,454 positive tests), and 9.3% with RSV alone (13,207 positive tests). Patients with multiple viruses showed an 8.7% rate, while the all-negative group had 8.9%.

Mortality rates were 1.9% for SARS-CoV-2 alone, 0.8% for influenza alone, and 1.1% for RSV alone. The all-negative group experienced a 2.0% death rate. Associations were estimated using multivariable logistic regression adjusted for age and immune-suppressive drugs. Confidence intervals for influenza and RSV indicated statistically significant differences relative to SARS-CoV-2 alone, whereas the multiple viruses group showed no significant difference.

Limitations include the observational nature of the design, which precludes causal inference. The study did not report specific adverse events, discontinuations, or detailed tolerability data. Follow-up duration was not reported. These results describe associations within a large healthcare system and may not apply to all populations.

  • Co-infections with COVID, flu, and RSV are extremely rare
  • Findings help older adults and high-risk patients understand true risks
  • Results are real-world data — already happening in clinics now

This study changes how we see respiratory virus threats.

It’s winter. Your throat is scratchy. Your chest feels tight. You test positive for flu — but should you worry about something worse? What if you had two or even three viruses at once? For years, doctors feared the worst: that catching multiple respiratory viruses could be a fast track to serious illness. But new data from over 800,000 patients shows something surprising.

Turns out, getting hit with multiple viruses at once is very rare. And when it does happen, it doesn’t appear to be more dangerous than having just one.

Respiratory viruses like COVID-19, flu, and RSV spread every year. They hit older adults and people with weak immune systems the hardest. Millions get sick. Some end up in the hospital. Oxygen drops. Lives are lost.

For years, doctors have worried about “tripledemic” seasons — when all three viruses surge at once. The fear? That catching more than one virus could overwhelm the body. That’s why many hospitals began testing patients for all three at the same time.

But until now, we didn’t have clear data on how often co-infections happen — or how dangerous they really are.

The surprising shift

We used to think: more viruses = sicker patients. It made sense. If one virus stresses the lungs, surely two or three would make it worse.

But here’s the twist: this large study found no proof of that.

In fact, patients with multiple viruses — like flu and RSV, or COVID and flu — were not at higher risk of low oxygen or death compared to those with just one virus.

What scientists didn’t expect

Even more surprising? Patients with only flu or only RSV were less likely to die than those with only COVID-19.

Yes, you read that right.

After adjusting for age and other health factors, people with flu or RSV alone had about half the risk of death compared to those with only COVID-19.

Think of your lungs like a busy highway. A viral infection is like a traffic jam — it slows things down. Oxygen can’t move freely. Your body struggles.

We assumed that two viruses would be like a multi-car pileup — total gridlock.

But this study suggests it’s not that simple. The body may handle multiple viruses in ways we don’t fully understand yet. Maybe one virus blocks another. Or maybe the immune response is different when more than one invader shows up.

Real-world data, real patients

This isn’t a lab experiment. It’s real life.

Researchers looked at more than 835,000 patients in the U.S. Veterans Health Administration who were tested for all three viruses at once during the 2022–2023 season. That’s a huge group — mostly older men, many with chronic health conditions.

They tracked who got sick, who needed oxygen, and who died — focusing on the first week after a positive test.

Out of all tested patients, only 1 in 500 — just 0.2% — had more than one virus.

That’s rare.

Among those with multiple infections, 8.7% had low oxygen levels. 1.5% died.

Compare that to:

  • 8.0% with low oxygen and 1.9% dying from COVID alone
  • 9.3% with low oxygen and 1.1% dying from RSV alone
  • 7.7% with low oxygen and 0.8% dying from flu alone

When researchers adjusted for age and immune-suppressing drugs, the results held.

Having multiple viruses didn’t increase the odds of low oxygen or death.

But there’s a catch.

This doesn’t mean this treatment is available yet.

Wait — no treatment? That’s right. This isn’t about a new drug or vaccine. It’s about understanding risk.

And that’s powerful.

The hidden danger

Here’s what stood out: patients who tested negative for all three viruses still had high rates of low oxygen (8.9%) and death (2.0%).

That suggests other causes — like bacterial pneumonia, heart failure, or undiagnosed conditions — may be driving severe illness just as much as these viruses.

This study helps clear up confusion during busy respiratory seasons. Because testing was routine, it avoided a major flaw in past research: only testing the sickest patients. That skewed results.

Now, we see the full picture — including people with mild symptoms.

The data suggests we should keep focusing on preventing and treating each virus individually — especially COVID-19, which still carries the highest risk of death in this group.

If you’re older or have a chronic illness, this should be reassuring.

The chance of catching multiple viruses at once is very low. And if you do, it doesn’t appear to make things worse.

Stay up to date on vaccines for COVID, flu, and RSV. They still offer the best protection.

Talk to your doctor about your personal risk — especially if you’re on immune-suppressing drugs.

The big unknown

This study looked only at veterans — mostly older men. Results might differ for women, younger adults, or children.

Also, it only tracked outcomes in the first week. Longer-term effects are still unknown.

What’s next

Public health teams can use this data to plan better for future virus seasons. No need to panic over co-infections — they’re rare.

But vigilance still matters. Vaccines, early testing, and prompt care remain key.

Research will continue to track how these viruses behave — especially as new variants emerge.

More studies are needed to confirm these findings in broader populations. But for now, the message is clear: focus on prevention, not fear.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Routine testing for SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) was deployed in a large US healthcare system in 2022–2023. This policy allowed identification of a large cohort of co-infected patients and comparison of outcomes without confounding by testing indication. Patients “triple-tested” in the US Veterans Health Administration were classified by infection status in the first week of a positive test. Multivariable logistic regression was used to estimate associations of different infections with hypoxemia (SpO2 2 L/min) or death, separately, expressed as adjusted odds ratios (aOR) with 95% confidence intervals (CI). Among 835,987 triple-tested patients, 170,592 (20.4%) tested positive for SARS-CoV-2 alone, 30,454 (3.6%) influenza alone, 13,207 (1.6%) RSV alone, and 1,300 (0.2%) multiple viruses. Frequencies of hypoxemia and death were 8.0 and 1.9% with SARS-CoV-2, 7.7 and 0.8% with influenza, 9.3 and 1.1% with RSV, 8.7 and 1.5% with multiple viruses, and 8.9 and 2.0% with all-negative tests. After adjustment for age and immune-suppressive drugs, odds of hypoxemia were slightly higher with influenza (aOR = 1.12, CI 1.06–1.17), lower with RSV (aOR = 0.91, CI 0.85–0.97), and not significantly different with multiple viruses (aOR = 1.09, CI 0.89–1.34), relative to SARS-CoV-2 alone. Odds of death were lower with influenza (aOR = 0.52, CI 0.46–0.60) or RSV (aOR = 0.51, CI 0.43–0.60) and no different with multiple infections (aOR = 0.86, CI 0.54–1.36), relative to SARS-CoV-2 alone. Co-infection was rare (0.2% of tested cases), with incidences of hypoxemia and death similar to SARS-CoV-2 alone. Death was less frequent with influenza or RSV than SARS-CoV-2.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.